Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …

In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC),
has undergone significant changes due to the introduction of targeted therapies and …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based
immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of …

Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a
subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling …

Brain tumors represent a heterogeneous group of neoplasms characterized by a high
degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the …

The endocytic trafficking pathway is a highly organized cellular program responsible for the
regulation of membrane components and uptake of extracellular substances. Molecules …

Animal models, particularly genetically engineered mouse models (GEMMs), continue to
have a transformative impact on our understanding of the initiation and progression of …